Provided by Tiger Trade Technology Pte. Ltd.

Context Therapeutics Inc.

2.38
+0.01000.42%
Volume:297.14K
Turnover:703.86K
Market Cap:218.67M
PE:-6.26
High:2.43
Open:2.37
Low:2.32
Close:2.37
52wk High:3.62
52wk Low:0.4900
Shares:91.88M
Float Shares:39.87M
Volume Ratio:0.55
T/O Rate:0.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3800
EPS(LYR):-0.3800
ROE:-46.39%
ROA:-29.79%
PB:3.62
PE(LYR):-6.26

Loading ...

Context Therapeutics announces annual shareholder meeting

Reuters
·
Apr 18

Neogen names Jennifer Evans Stacey chief legal, compliance officer, board secretary

Reuters
·
Apr 08

JonesTrading Remains a Buy on Context Therapeutics (CNTX)

TIPRANKS
·
Apr 07

Analysts Are Bullish on These Healthcare Stocks: Femasys (FEMY), Context Therapeutics (CNTX)

TIPRANKS
·
Apr 02

Context Therapeutics Gains FDA Fast Track for CTIM-76

TIPRANKS
·
Apr 02

Context Therapeutics granted Fast Track Designation to CTIM-76 by FDA

TIPRANKS
·
Apr 02

Context Therapeutics’ CTIM-76 wins FDA fast-track status for platinum-resistant ovarian cancer

Reuters
·
Apr 02

Context Therapeutics - Ctim-76 Phase 1a Trial Ongoing, Interim Data Expected June 2026

THOMSON REUTERS
·
Apr 02

Context Therapeutics Announces Ctim-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer

THOMSON REUTERS
·
Apr 02

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 25

Guggenheim Reaffirms Their Buy Rating on Context Therapeutics (CNTX)

TIPRANKS
·
Mar 24

Context Therapeutics FY Net Loss Narrows

MT Newswires Live
·
Mar 24

Context Therapeutics Highlights Evolving T Cell Engager Pipeline

TIPRANKS
·
Mar 24

BRIEF-Context Therapeutics Reports Full Year 2025 Operating And Financial Results

Reuters
·
Mar 24

Context Therapeutics targets June 2026 interim Phase 1a data for CTIM-76 bispecific antibody trial

Reuters
·
Mar 24

Context Therapeutics: Cash and Cash Equivalents of $66 Mln as of December 31, 2025 Expected to Fund Operations Into Mid-2027

THOMSON REUTERS
·
Mar 24

Context Therapeutics FY 2025 net loss widens 35% to USD 36 million

Reuters
·
Mar 24

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 23

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 20

Context Therapeutics to present CT-202 preclinical data at AACR Annual Meeting 2026

Reuters
·
Mar 19